Get the Stockscreener App
6.58
4.28%
0.27
89 Bio Inc stock is traded at $6.58, with a volume of 1.55M.
It is up +4.28% in the last 24 hours and down -17.13% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$6.31
Open:
$6.38
24h Volume:
1.55M
Relative Volume:
1.58
Market Cap:
$773.69M
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-3.3401
EPS:
-1.97
Net Cash Flow:
$-165.54M
1W Performance:
+4.78%
1M Performance:
-17.13%
6M Performance:
-21.20%
1Y Performance:
-40.40%
1-Day Range:
$6.335
$6.61
1-Week Range:
$5.9857
$6.65
52-Week Range:
$5.9857
$16.63
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
6.58 | 773.69M | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
89bio shares maintain Buy rating as analyst cites confidence in pegozafermin trial outcomes - MSN
HC Wainwright Reiterates Buy Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Hennion & Walsh Asset Management Inc. Takes $739,000 Position in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio (NASDAQ: ETNB) Provides Corporate Update and Business Outlook for 2025SAN FRANCISCO, January 13, 2025 (GLOBE NEWSWIRE) – 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in innovative therapies for l - Defense World
Weiss Ratings Reiterates “Sell (D-)” Rating for 89bio (NASDAQ:ETNB) - Defense World
89bio, Inc. (NASDAQ:ETNB) Short Interest Up 12.2% in December - MarketBeat
89bio (NASDAQ:ETNB) Hits New 12-Month Low After Insider Selling - Defense World
89bio, Inc. (NASDAQ:ETNB) Insider Sells $71,149.87 in Stock - MarketBeat
89bio's chief technical operations officer sells $71,149 in stock - MSN
89bio's chief technical operations officer sells $71,149 in stock By Investing.com - Investing.com South Africa
89bio (NASDAQ:ETNB) Stock Price Down 4%Time to Sell? - MarketBeat
89bio (NASDAQ:ETNB) Reaches New 12-Month LowTime to Sell? - MarketBeat
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward (NASDAQ:ETNB) - Seeking Alpha
89bio Provides Business Update and Outlook for 2025 - The Manila Times
89bio Completes Phase 3 Trial Enrollment, Fortifies Position with $440M Cash Reserve - StockTitan
89bio (NASDAQ:ETNB) Sets New 1-Year Low – Should You Sell? - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Acquired by Barclays PLC - MarketBeat
Barclays PLC Acquires 149,479 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
Certain Warrant of 89bio, Inc. are subject to a Lock-Up Agreement Ending on 12-JAN-2025. - Marketscreener.com
89bio (NASDAQ:ETNB) Hits New 52-Week LowHere's Why - MarketBeat
89bio stock hits 52-week low at $6.42 amid market challenges By Investing.com - Investing.com South Africa
89bio stock hits 52-week low at $6.42 amid market challenges - Investing.com Australia
89bio (NASDAQ:ETNB) Stock Price Down 8.2%Here's What Happened - MarketBeat
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking - The Globe and Mail
Biotech manufacturer plans to cut 120 jobs in Durham - WRAL News
Brokerages Set 89bio, Inc. (NASDAQ:ETNB) PT at $30.33 - Defense World
89bio's SWOT analysis: pegozafermin potential drives stock outlook By Investing.com - Investing.com Australia
89bio (NASDAQ:ETNB) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
89bio’s SWOT analysis: pegozafermin potential drives stock outlook By Investing.com - Investing.com Nigeria
89bio's SWOT analysis: pegozafermin potential drives stock outlook - Investing.com India
89bio (NASDAQ:ETNB) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Head to Head Review: VectivBio (NASDAQ:VECT) versus Tourmaline Bio (NASDAQ:TRML) - Defense World
89bio (NASDAQ:ETNB) Stock Price Down 3.7%Should You Sell? - MarketBeat
Jane Street Group LLC Has $1.03 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Jane Street Group LLC Has $1.03 Million Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Has $15.36 Million Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
Barclays PLC Boosts Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Barclays PLC Raises Stock Position in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Holdings Reduced by Franklin Resources Inc. - MarketBeat
89bio Grants Retention RSUs to Key Officers - Defense World
State Street Corp Acquires 7,184 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Sets New 52-Week Low – Here’s Why - Defense World
89bio (NASDAQ:ETNB) Sets New 52-Week LowHere's Why - MarketBeat
89bio stock hits 52-week low at $6.96 amid market challenges - Investing.com Canada
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):